scholarly journals PERAN ESTROGEN DAN PROGESTERON TERHADAP KANKER PAYUDARA

2014 ◽  
Vol 6 (3) ◽  
Author(s):  
Erna Suparman ◽  
Eddy Suparman
Keyword(s):  
Hormone Replacement Therapy ◽  
Venous Thromboembolism ◽  
Replacement Therapy ◽  
Steroid Hormones ◽  
Hormone Replacement ◽  
Sex Steroid Hormones ◽  
Sex Steroid ◽  
Breast Cancers ◽  
Health Initiative ◽  
Breast Cells

Abstract: Sex steroid hormones estrogen and progesterone are the main compounds in hormone replacement therapy (HRT). Due to the Woman’s Health Initiative report 2002, the use of these compounds was controversial. It was reported that these hormones increased the risks of stroke, coronary heart disease, venous thromboembolism, and breast cancer, especially if they were used for a long period of time. The role of sex steroid hormones in inducing or promoting breast malignancy is still not clearly understood. Hypothetically, the polymorphism in receptors and steroidogenesis in breast tissues are involved in promoting the proliferation of breast cells that may trigger carcinogenesis. Although there is a significant benefit in administration of HRT for the menopausal women, there are also probable risks due to this therapy. After prolonged debates and controversies about HRT, it is accepted that there is a significant increase in breast cancers due to the use of combined HRT after 3-4 years. Due to the adverse outcome, the use of hormone therapy must start from the lowest dose and for the shortest period of time.Keywords: hormone replacement therapy, estrogen, progesterone, breast cancerAbstrak: Hormon seks steroid estrogen dan progesteron merupakan kandungan utama dari terapi sulih hormone (TSH). Penggunaan kedua hormon tersebut mendatangkan kontroversi setelah Woman’s Health Initiative pada tahun 2002 melaporkan peningkatan risiko stroke, penyakit jantung koroner, venous thromboembolism dan kanker payudara terutama pada penggunaan jangka panjang. Peran hormon steroid seks dalam meningkatkan keganasan payudara belum jelas dipahami. Secara hipotetik, polimorfisme pada reseptor dan kemampuan steroidogenesis dari jaringan payudara berperan dalam meningkatkan proliferasi sel-sel payudara dan memicu karsinogenesis. Meskipun terdapat keuntungan bermakna dari penggunaan TSH pada wanita menopause, namun terdapat juga kemungkinan risiko yang perlu dipertimbangkan. Setelah melalui berbagai perdebatan dan kontroversi mengenai TSH, disepakati bahwa terdapat peningkatan bermakna dari keganasan payudara setelah 3-4 tahun menggunakan TSH kombinasi. Oleh karena efek samping tersebut maka penggunaan TSH harus dimulai dengan dosis yang serendah mungkin dengan durasi pemakaian yang sesingkat-singkatnya.Kata kunci: terapi sulih hormon, estrogen, progesteron, kanker payudara

ARE BREAST CANCERS IN PATIENTS ON HORMONE REPLACEMENT THERAPY DIFFERENT FROM THE CLASSICAL BREAST CANCER?

2003 ◽  
Vol 13 (Suppl 1) ◽  
pp. 30.1-30
Author(s):  
M. Aerts ◽  
P. Neven ◽  
R. Drijkoningen ◽  
L. Morales ◽  
R. Paridaens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Hormone Replacement ◽  
Breast Cancers

scholarly journals Hormone replacement therapy in women with cancer and risk of cancer-specific mortality and cardiovascular disease: a protocol for a cohort study from Scotland and Wales

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Úna McMenamin ◽  
Blánaid Hicks ◽  
Carmel Hughes ◽  
Peter Murchie ◽  
Julia Hippisley-Cox ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Hormone Replacement Therapy ◽  
Venous Thromboembolism ◽  
Replacement Therapy ◽  
Cancer Diagnosis ◽  
Hormone Replacement ◽  
All Cause Mortality ◽  
Specific Mortality ◽  
Cancer Specific Mortality ◽  
Risk Of Cancer

Abstract Background Hormone replacement therapy (HRT) is widely used and has proven benefits for women with menopausal symptoms. An increasing number of women with cancer experience menopausal symptoms but the safety of HRT use in women with cancer is unclear. There are particular concerns that HRT could accelerate cancer progression in women with cancer, and also that HRT could increase the risk of cardiovascular disease in such women. Therefore, our primary aim is to determine whether HRT use alters the risk of cancer-specific mortality in women with a range of common cancers. Our secondary objectives are to investigate whether HRT alters the risk of second cancers, cardiovascular disease, venous thromboembolism and all-cause mortality. Methods The study will utilise independent population-based data from Wales using the SAIL databank and Scotland based upon the national Prescribing Information System. The study will include women newly diagnosed with common cancers from 2000 to 2016, identified from cancer registries. Women with breast cancers will be excluded. HRT will be ascertained using electronic prescribing in Wales or dispensing records in Scotland. The primary outcome will be time to cancer-specific mortality from national mortality records. Time-dependent cox regression models will be used to calculate hazard ratios (HR) and 95% confidence intervals (95% CIs) for cancer specific death in HRT users compared with non-users after cancer diagnosis after adjusting for relevant confounders, stratified by cancer site. Analysis will be repeated investigating the impact of HRT use immediately before cancer diagnosis. Secondary analyses will be conducted on the risk of second cancers, cardiovascular disease, venous thromboembolism and all-cause mortality. Analyses will be conducted within each cohort and pooled across cohorts. Discussion Our study will provide evidence to inform guidance given to women diagnosed with cancer on the safety of HRT use and/or guide modifications to clinical practice.

Sex steroid hormones enhance immune function in male and female Siberian hamsters

2001 ◽  
Vol 280 (1) ◽  
pp. R207-R213 ◽  
Author(s):  
Staci D. Bilbo ◽  
Randy J. Nelson
Keyword(s):  
Immune Function ◽  
Steroid Hormones ◽  
Lymphocyte Proliferation ◽  
Hormone Replacement ◽  
Sex Steroid Hormones ◽  
Sex Steroid ◽  
Cell Mediated Immunity ◽  
Estradiol Treatment ◽  
Male And Female ◽  
Siberian Hamsters

Immune function is better in females than in males of many vertebrate species, and this dimorphism has been attributed to the presence of immunosuppressive androgens in males. We investigated the influence of sex steroid hormones on immune function in male and female Siberian hamsters. Previous studies indicated that immune function was impaired in male and female hamsters housed under short-day photoperiods when androgen and estrogen concentrations were virtually undetectable. In experiment 1, animals were gonadally intact, gonadectomized (gx), or gx with hormone replacement. Females exhibited the expected increase in antibody production over males, independent of hormone treatment condition, whereas male and female gx animals exhibited decreased lymphocyte proliferation to the T cell mitogen, phytohemagglutinin (PHA) compared with intact animals, and this effect was reversed in gx hamsters following testosterone and estradiol treatment, respectively. In experiment 2, testosterone, dihydrotestosterone, and estradiol all enhanced cell-mediated immunity in vitro, suggesting that sex steroid hormones may be enhancing immune function through direct actions on immune cells. In experiment 3, an acute mitogen challenge of lipopolysaccharide significantly suppressed lymphocyte proliferation to PHA in intact males but not females, suggesting that males may be less reactive to a subsequent mitogenic challenge than females. Contrary to evidence in many species such as rats, mice, and humans, these data suggest that sex steroid hormones enhance immunity in both male and female Siberian hamsters.

Hormone replacement therapy on ovarian and uterine cancer risk and cancer survivors: how shall we do no harm?

2005 ◽  
Vol 15 (3) ◽  
pp. 420-425 ◽  
Author(s):  
V. Loizzi ◽  
G. Cormio ◽  
M. Vicino ◽  
N. Fattizzi ◽  
S. Bettocchi ◽  
...  
Keyword(s):  
Hormone Replacement Therapy ◽  
Cancer Risk ◽  
Cancer Survivors ◽  
Replacement Therapy ◽  
Uterine Cancer ◽  
Hormone Replacement ◽  
Gynecologic Cancer ◽  
Cancer Data ◽  
Health Initiative ◽  
Do No Harm

This article will focus on the results of the Women's Health Initiative on the effects of hormone replacement therapy on coronary heart disease, stroke, venous thromboembolism, breast cancer, and colorectal cancer. Data from other relevant trials, including the most recent data on ovarian and uterine cancer risk and on gynecologic cancer patients, are also discussed to provide some guidelines on prescribing hormone replacement therapy in clinical practice, particularly in gynecologic cancer survivors.

Sign in / Sign up

Export Citation Format

Share Document